Curcumin prophylaxis mitigates the incidence of hypobaric hypoxia-induced altered ion channels expression and impaired tight junction proteins integrity in rat brain

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Sarada, S K S ^a   Titto, M ^a   Himadri, P ^a   Saumya, S ^a   Vijayalakshmi, V ^a  

^a DEFENCE INSTITUTE OF PHYSIOLOGY AND ALLIED SCIENCES   (India)

Author keywords

Cerebral edema; Curcumin; ENaC; Fluid reabsorption; HIF 1a ; Hypoxia; Inflammation; Na^{+< sup> K+< sup> ATPase; NF B; Tight junction proteins}

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CLAUDIN 4; CLAUDIN 5; CURCUMIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPITHELIAL SODIUM CHANNEL; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 2; ION CHANNEL; JUNCTIONAL ADHESION MOLECULE C; PADGEM PROTEIN; PROTEIN ZO1; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYTOKINE; HIF1A PROTEIN, RAT; TRANSCRIPTION FACTOR;

ALTITUDE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN EDEMA; BRAIN HYPOXIA; BRAIN WATER; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ERYTHROCYTE COUNT; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TIGHT JUNCTION; UPREGULATION; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HYPOXIA; INCIDENCE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN EDEMA; CURCUMIN; CYTOKINES; DISEASE MODELS, ANIMAL; EPITHELIAL SODIUM CHANNELS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INCIDENCE; ION CHANNELS; MALE; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-POTASSIUM-EXCHANGING ATPASE; TIGHT JUNCTION PROTEINS; TRANSCRIPTION FACTORS;

EID: 84931273528     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0326-4     Document Type: Article

References (75)

1. Hackett PH, Roach RC. High altitude cerebral edema. High Alt Med Biol. 2004;5:136-46.
2. Wilson M, Newman SM, Imray C. The cerebral effects of ascent to high altitude. Lancet Neurol. 2009;8(2):175-91.
3. Dickinson J. Severe acute mountain sickness. Postgrad Med J. 1979;55:454-8.
4. Clarke C. High altitude cerebral oedema. Int J Sports Med. 1988;9:170-4.
5. Basnyat B, Subedi D, Sleggs J, Lemaster J, Bhasyal G, Aryal B, et al. Disoriented and ataxic pilgrims: an epidemiological study of acute mountain sickness and high altitude cerebral edema at a sacred lake at 4300 m in the Nepal-Himalayas. Wilderness-Environ-Med. 2000;11:89-93.
6. Schoch HJ, Fischer S, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain. 2002;125:2549-57.
7. Kallenberg K, Dehnert C, Dörfler A, Schellinger PD, Bailey DM, Knauth M, et al. Microhemorrhages in nonfatal high-altitude cerebral edema. J Cereb Blood Flow Metab. 2008;28:1635-42.
8. Stelzner TJ, O'Brien RF, Sato K, Wail JV. Hypoxia induced increase in pulmonary transvascular protein escape in rats: modulation by glucocorticoids. J Clin Intvention. 1988;82:1840-7.
9. Mark SK, Davis TP. Cerebral micro vascular changes in permeability and tight junctions induced by hypoxia reoxygenation. Am J Physiol Heart Circ Physiol. 2002;282:H1485-94.
10. Tsukamoto T, Nigam SK. Role of tyrosine phosphorylation in the reassembly of occluding and other tight junction proteins. Am J Physiol Renal Physiol. 1999;276(5):F737-50.
11. Tsukita S, Furuse M. Occludin and claudins in tight junction strands: leading or supporting players? Trends Cell Biol. 1999;9:268-73.
12. Itoh M, Furuse M, Morita K, Kubota K, Saitou M, Tsukita S. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of Cludins. J Cell Biol. 1999;147:1351-63.
13. Kristian T, Siesjo BK. Calcium in ischemic cell death. Stroke. 1998;29:705-18.
14. Madjdpour C, Jewell UR, Kneller S, Ziegler U, Schwendener R, Booy C, et al. Decreased alveolar oxygen induces lung inflammation. Am J Physiol Lung Cell Mol Physiol. 2003;284:L360-7.
15. Himadri P, Sarada SK, Chitharanjan M, Dhananjay S. Role of oxidative stress and inflammation in hypoxia-induced cerebral edema: a molecular approach. High Alt Med Biol. 2010;11:231-44.
16. Grissom CK, Roach RC, Sarnquist FH, Hackett PH. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med. 1992;116:461-5.
17. Milledge JS, West JB, Schoene RB. High altitude cerebral edema. In: High altitude medicine and physiology. 3rd ed. London: Hodder Arnold; 2000. p. 248.
18. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggrawal BB. Curcumin and cancer: an old disease with an age old solution. Cancer Lett. 2008;267:133-64.
19. Piper JT, Singhal SS, Salameh M, Torman RT, Awasthi YC, Awasthi S. Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol. 1998;30:445-56.
20. Thapliyal R, Maru GB. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol. 2001;39:541-7.
21. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 1995;94:79-83.
22. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappa B activation via the NIK/IKK signalling complex. Oncogene. 1999;18:6013-20.
23. Brennan P, O'Neill LA. Inhibition of nuclear factor kappaB by direct modification in whole cells-mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochem Pharmacol. 1998;55:965-73.
24. Benjamin H, Theis MK, Jane KM, Roach R, Yip HC, Moore LG. Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med. 1993;118:587-92.
25. Kohli K, Ali J, Ansari MJ, Raheman Z. Curcumin: a natural anti-inflammatory agent. Indian J Pharmacol. 2004;37(3):141-7.
26. Majeed M, Badmaev V, Shivakumar U, Rajendran R. Curcuminoids-antioxidant phytonutrients. Piscataway, NJ: Nutriscience Publishers Inc.; 1995.
27. Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmaco. 1999;58:1167-72.
28. Barik A, Priyadarsini KI, Mohan H. Photophysical studies on binding of curcumin to bovine serum albumins. Photochem Photobiol. 2003;77:597-603.
29. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology. 1980;16:259-65.
30. Sahdeo P, Amit KT, Bharat BA. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat. 2014;46(1):2-18.
31. Basu M, Sawney RC, Kumar S, Pal K, Prasad R, Selwamurthy W. Glucocorticoids as prophylaxis against acute mountain sickness. Clin Endocrinol. 2002;57:761-7.
32. Baba M, Oshi R, Saeki K. Enhancement of blood-brain barrier permeability to sodium fluorescence by stimulation of mu opiod receptors in mice. Naunyn Schmiedeberges Arch Pharmacol. 1998;337:423-8.
33. Hu X, Taylor ON, Qiu J, Rea HC, Fabian R, Rassin DK, et al. Activation of nuclear factor-kB signaling pathway by interleukin-1 after hypoxia/ischemia in neonatal rat hippocampus and cortex. J Neurochem. 2005;93:26-37.
34. Beytut E, Soznen M, Erginosoy E. Immunohistochemical detection of pulmonary surfactant protein and retro viral antigen in lungs of sheep with pulmonary adenomatoris. J Comparative Pathol. 2009;140:45-53.
35. Ward MP, Milledge JS, West JB. High altitude medicine and physiology. 2nd ed. London: Chapman & Hall Medical; 1995.
36. Saunders PU, Pyne DB, Gore CJ. Endurance training at altitude. High Altitude Med Biol. 2009;10:135-48.
37. Fudge BW, Pringle JSM, Maxwell NS, Turner G, Ingham SA, Jones AM. Altitude training for elite endurance performance: a 2012 update. Curr Sports Med Reports. 2012;11(3):148-54.
38. Garvican L, Martin D, Quod M, Stephens B, Sassi A, Gore C. Time course of the hemoglobin mass response to natural altitude training in elite endurance cyclists. Scand J Med Sci Sports. 2012;22(1):95-103.
39. Pottgiesser T, Garvican LA, Martin DT, Featonby JM, Gore CJ, Schumacher YO. Short term haematological effects upon completion of a four week simulated altitude camp. Int J Sports Physiol Perf. 2012;7:79-83.
40. Van Den P, Kenneth NSM, Rocha S. Regulation of hypoxia-inducible factor 1-alpha by NF-kappaB. Biochem J. 2008;15:477-84.
41. Stanimirovic D, Satoh K. Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation. Brain Pathol. 2000;10:113-26.
42. Holger KE, Peter C. Hypoxia and Inflammation. N Engl J Med. 2011;364:656-65.
43. Arbiser JL, Klauber N, Rohan R, Van Leewen R, Huangmt MT, Fisher C, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998;4:376-83.
44. Lukiw WJ, Ottlecz A, Lambrou G, Grueninger M, Finley J, Thompson HW, et al. Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci. 2003;44:4163-70.
45. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1aα. Nature. 2008;5:807-11.
46. Xiong M, Elson G, Legasda D, Leibovich SM. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol. 1998;153:587-98.
47. Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E. VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaB alpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci. 2003;116:665-74.
48. Robert W, Sean BJ, Bryan A, Laffitte AC, Lining P, Peter T. Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptor. J Biol Chem. 2004;279(11):9905-11.
49. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol. 1999;237:97-132.
50. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NFKB activity decreases the VEGF mRNA expression in MDA-MB-231. Breast Cancer Cells Treat. 2002;73:237-43.
51. Witt KA, Mark KS, Hom S, Davis TP. Effects of hypoxia reoxygenation on rat blood brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol. 2003;285:H2820-31.
52. Garcia-Alloza M, Bottelli LA, Rozkalhe A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques and partially restores distorted nutrients in an Alzheimer mouse model. J Neurochem. 2007;102:1095-104.
53. Ryu EK, Choe YS, Lee KH, Choi Y, Kim BT. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006;49:6111-9.
54. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895-900.
55. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;15:200410-6847.
56. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006;4:1035-8.
57. Durgaprasad S, Pai CG, Vasanth K, Alvres JF, Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res. 2005;122(4):315-8.
58. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191-3.
59. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:1502-6.
60. Rasyid A, Rahman AR, Jaalam K, Lelo A. Effect of different curcumin dosages on human gall bladder. Asia Pac J Clin Nutr. 2002;11(4):314-8.
61. Heng MC, Song MK, Harker J, Heng MK, et al. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol. 2000;143:937-49.
62. Di Mario F, Cavallaro LG, Nouvenne A, Stefani N, Cavestro GM, Iori V, et al. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? Helicobacter. 2007;12:238-43.
63. Yang GY, Chen SF, Kinouchi H, Chan PH, Weinstein PR. Edema, cation content, and ATPase activity after middle cerebral artery occlusion in rats. Stroke. 1992;23:1331-6.
64. Siesjö BK. Pathophysiology and treatment of focal cerebral ischemia: Part II: mechanisms of damage and treatment. J Neurosurg. 1992;77(3):337-54.
65. Behl C, Moosmann B. Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. Biol Chem. 2002;383:521-36.
66. Hennings H, Yuspa SH, Holbrook KA. Inhibition of calcium-induced terminal differentiation of epidermal cells by ouabain and A23187. Curr Probl Dermatol. 1983;11:109-25.
67. Heerlein K, Schulze A, Holtz L, Bartsch P, Mairbaurl H. Hypoxia decreases cellular ATP demand and inhibits mitochondrial respiration of A549 cells. Am J Respi Cell Mol Biol. 2005;32:44-51.
68. Fischer S, Wobben M, Kleinstuck J, Renz D, Schaper W. Effect of astroglial cells on hypoxia-induced permeability in PBMEC cells. Am J Physiol Cell Physiol. 2000;279:C935-44.
69. Sharkey AM, Day K, Mc P, Malik S, Licence D, Smith SK, et al. Vascular endothelial growth factor expression in human endometrium and regulated by hypoxia. J Clin Endocrinal Metab. 2000;85:402-9.
70. Zoppo GD, Ginis I, Hallenbeck JM, Indecola C, Wang X, Feuerstein GZ. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 2000;10:95-112.
71. Qiquan Z, Xiaoling T, Jing W, Bo Z, Ping G. Increased permeability of blood-brain barrier caused by inflammatory mediators is involved in high altitude cerebral edema. Sci Res Essays. 2011;6(3):607-15.
72. Firouzi Z, Lari P, Rashedinia M, Ramezani M, Iranshahi M, Abnous K. Proteomics screening of molecular targets of curcumin in mouse brain. Life Sci. 2014;98(1):12-7.
73. Hackett PH. The cerebral etiology of high altitude cerebral edema and acute mountain sickness. Wilderness Environ Med. 1999;10(2):97-109.
74. Cymerman A, Rock PB. Medical problems in high mountain environments: a handbook for medical officers. US ARIEM Techn Note. 1994;94-2:1-49.
75. Ling NH, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Arch Gen Psychiatry. 1981;38:471-7.